Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe.

Javier P GisbertPetra StreitIsabel RedondoSusanne HartzHannah KnightEmily Quinones Niamh HarveyVanda PalaceTheresa Hunter Gibble

Published in: Current medical research and opinion (2023)

Over 10% of patients were receiving a higher-than-standard dose of vedolizumab, but despite this were found to have suboptimal clinical outcomes and low physician satisfaction.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
emergency department
primary care
patients with inflammatory bowel disease
prognostic factors
peritoneal dialysis
type diabetes
insulin resistance